Trial · NCT02868801
Efficacy and Safety of Pregabalin Sustained Release Tablet for Postherpetic Neuralgia
NCT02868801, Phase 3, Unknown, Jiangsu HengRui Medicine Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of Pregabalin Sustained Release Tablet for Postherpetic Neuralgia. Trials, record NCT02868801. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02868801
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of Pregabalin Sustained Release Tablet for Postherpetic Neuralgia
- NCT number
- NCT02868801
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 280 participants, estimated
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Conditions
- Postherpetic Neuralgia
- Interventions
- Placebo, Pregabalin SR tablet 165mg/day, Pregabalin SR tablet 330mg/day, Pregabalin SR tablet 660mg/day
- First posted
- 2016-08-16
- Last updated
- 2016-08-16
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Responders | 15 weeks | A responder is defined as a subject with a 30% reduction in weekly mean pain score from baseline to endpoint |
| Secondary | 50% reduction in weekly mean pain score from baseline to study completion | 15 weeks | |
| Secondary | Change of Mean Pain Scores from study completion to baseline | 15 weeks | |
| Secondary | Change of Mean Sleep Interference Scores from study completion to baseline | 15 weeks |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 16466610 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02868801
GET https://conductscience.org/api/trials/v1/NCT02868801/registered